Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Xu, Jie ^a,b   Wu, Xing ^a,c   Zhou, Wei hua ^a,b   Liu, An wen ^b   Wu, Jian bing ^b   Deng, Jin yun ^d   Yue, Cai feng ^a   Yang, Shao bing ^e   Wang, Jing ^a   Yuan, Zhong yu ^a   Liu, Quentin ^a,c,f  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b NANCHANG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Jiangxi Province Cancer Hospital   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE;

EID: 84874286150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056919     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Prat A, Baselga J, (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5: 531-542.
3. Brenton JD, Carey LA, Ahmed AA, Caldas C, (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application. J Clin Oncol 23: 7350-7360.
4. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
6. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, et al. (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42: 3149-3156.
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V, (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
8. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, et al. (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20: 1913-1927.
9. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, et al. (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018.
10. Keam B, Im SA, Lee KH, Han SW, Oh DY, et al. (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13: R22.
11. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, et al. (2009) Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 20: 1639-1646.
12. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
13. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, et al. (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27: 4701-4708.
14. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32.
15. Marumoto T, Zhang D, Saya H, (2005) Aurora-A- a guardian of poles. Nat Rev Cancer 5: 42-50.
16. Liu Q, Ruderman JV, (2006) Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A 103: 5811-5816.
17. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, et al. (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148-7158.
18. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267.
19. Jeng YM, Peng SY, Lin CY, Hsu HC, (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10: 2065-2071.
20. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, et al. (2007) Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 67: 10436-10444.
21. Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T, et al. (2005) The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 1827-1834.
22. Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, et al. (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13: 4098-4104.
23. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, et al. (2009) Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8: 2461-2469.
24. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, et al. (1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 59: 2041-2044.
25. Miyoshi Y, Iwao K, Egawa C, Noguchi S, (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92: 370-373.
26. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, et al. (2008) Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14: 4455-4462.
27. Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y, et al. (2010) The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 70: 9118-9128.
28. Edge SB, Compton CC, (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
29. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, et al. (2003) Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107: 896-902.
30. Zhou WH, Tang F, Xu J, Wu X, Feng ZY, et al. (2011) Aberrant upregulation of 14-3-3o expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 11: 397-406.
31. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, et al. (2008) Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 29: 1930-1937.
32. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, et al. (2002) HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77: 148-154.
33. Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, et al. (2011) Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 105: 272-280.
34. Pan C, Yan M, Yao J, Xu J, Long Z, et al. (2008) Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol 44: 639-645.
35. Zhou WH, Tang F, Xu J, Wu X, Yang SB, et al. (2012) Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy 8.
36. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281.
37. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, et al. (2010) The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer 4: 35-41.
38. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
39. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657.
40. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
41. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, et al. (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16: 260-267.
42. Huang XF, Luo SK, Xu J, Li J, Xu DR, et al. (2008) Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111: 2854-2865.
43. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, et al. (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109(2): 500-502.
44. Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, et al. (2011) Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 67(2): 305-314.